
The company has launched a comprehensive portfolio of custom cell biology solutions and a new cell-line engineering technology.
The company has launched a comprehensive portfolio of custom cell biology solutions and a new cell-line engineering technology.
MilliporeSigma added a new cloud-based, remote lab water service and monitoring capability to its Milli-Q CLX 7000 clinical water purification system.
Distek, a provider of laboratory testing instruments, added a dual impeller single-use bioreactor (SUB) system to its BIOne portfolio.
Belgium-based CDMO MaSTherCell will expand its European manufacturing capacity for cell and gene therapy products by setting up a new facility in Belgium.
A continuous peptide manufacturing process invented by Swedish Biomimetics 3000 Ltd is a platform technology also applicable to other solid-phase chemical processes, such as chromatography.
Waters debuted a range of new TA Instruments innovations and the BioAccord System at Pittcon 2019 in Philadelphia, PA, on March 17–21, 2019.
Katalyst D2D from ACD/Labs enables the design, planning, execution, and analysis of high throughput (HT) experiments. The web-based application was introduced at Pittcon 2019 in Philadelphia, PA.
A $1.7-billion acquisition CDMO Brammer Bio establishes Thermo Fisher Scientific in viral vector manufacturing.
Bruker highlighted new analytical systems for several industry applications, including pharma, materials science, and clinical/preclinical research.
The companies aim to assess automated CAR-T cell therapy manufacturing at the point-of-care and develop technologies to facilitate patient access to immunotherapies.
Alcami Biologics formed to meet market demands for biological drug development services.
The Pharma Services business of Thermo Fisher Scientific will invest $150 Million at three facilities.
A $100-million investment will expand a range of the CDMO’s service capabilities and offerings.
Stream Bio entered into a new agreement with DBA Italia to launch Stream Bio’s nanotech-based bioimaging probes in Italy.
The collaboration’s enhanced data exchange combined with advanced analytics are expected to reduce raw material variability and improve biomanufacturing performance reliability.
The companies will join forces to improve gene- and cell-therapy manufacturing using the cloud and machine learning.
The acquisition of the site in Copenhagen, Denmark, will significantly expand Fujifilm’s capacity and capabilities.
OSE Immunotherapeutics has been granted authorization to commence a Phase I clinical trial for checkpoint inhibitor BI 765063 (previously OSE-172).
The new automated cloud-based tool allows for the design of targeted single-cell DNA custom panels.
The companies will use GeoVax’s vaccine technology to develop malaria vaccine candidates.
Sartorius Stedim Biotech (SSB) and Novasep will partner to develop systems for membrane chromatography using Novasep’s BioSC platform and SSB’s single-use technology.
The Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac partner to develop a transportable mRNA vaccine manufacturing platform.
A project conducted by research institute CEA-Leti led to the development of a new HIV vaccine approach based on engineered lipid nanoparticles.
The TSKgel FcR-IIIA-NPR HPLC column from Tosoh Bioscience is a FcRγ affinity chromatography analysis column suited for the analysis of immunoglobulin G glycoforms.
The $21.4-billion acquisition will create stand-alone business within Danaher’s life-sciences portfolio.
A multi-partner collaboration has been announced, which will target the acceleration of the development of automated microfluidic systems for rapid and high-throughput gene editing in mammalian cell lines.
India’s Bharat Biotech is set to acquire GlaxoSmithKline’s Chiron Behring Vaccines, a World Health Organization-prequalified global manufacturer of rabies vaccines.
Catalent adds position of president and chief operating officer to lead sales and quality efforts.
The partnership will expand Lonza’s offering of hematopoietic cell lines.
Pathios Therapeutics and Sygnature Discovery have signed a strategic and innovative partnership agreement aimed at accelerating Pathios’ drug discovery and development programs.